logo
Health Matters Newsletter: How to stay ready for future pandemics

Health Matters Newsletter: How to stay ready for future pandemics

The Hindu27-05-2025

It's time to address the elephant in the room: for a few weeks now, that elephant has been COVID-19. For some time now, the number of confirmed COVID cases have been rising in certain parts of the world, particularly in South East Asia. Meanwhile, India which had very nearly stopped routine testing for suspected COVID infections also picked up the cue, and began testing for the condition. A slow, and gradual increase was noticed, over the weeks. Bindu Shajan Perappadan recorded that the Active Covid cases in India had climbed to 1009 this week. About 305 people had been treated, and there were seven deaths last week.
What followed the news on rise in cases in South east asia was a great deal of panic reporting by sections of the media. Every case has been breathlessly reported, while forgetting that for a country with a 1.2 billion people, the current number of cases is hardly even a blip on the radar. Of course, the price of having gone through one ghastly pandemic is eternal vigilance, and we have learnt that the hard way. There is no doubt that testing has to be scaled up, vaccines and boosters should be made available again to all those who require it, and hospitals need to gear up in order to face a large scale crisis if one were to emerge in the future.
Do read Saima Wazed's important piece, in this context: A medical oxygen access gap SE Asia must bridge . South Asia and East Asia and the Pacific have the highest unfulfilled demand for medical oxygen (the oxygen service coverage gap in these two regions is 78% and 74% respectively), and there is a clear and urgent need for action to rectify this.
But, and this is key: there is not yet a COVID crisis in the country. Numbers still continue to be in the 100s range and most people seem to recover without major, notable complications. INSACOG has reported that most of the Sar-CoV-2 samples sequenced in India over the last couple of weeks were BA.2 and JN.1 variants, milder variants with home care sufficient for those who test positive. Officials in the Health Ministry also confirmed that there was no indication that the current variants cause more severe disease, but also that it was not more tranmissible than previously. However, as we learnt the last time, it is important to take care of people who are more vulnerable, have a robust surveillance network for picking up influenza like illnesses, and respiratory conditions.
For an explainer on What's behind the recent Covid-19 spike in India? , hit the link.
Amidst all this, that the WHO members adopted the 'pandemic agreement' born out of disjointed global COVID response came as good news. In short, the World Health Organization's member countries on approved an agreement to better prevent, prepare for and respond to future pandemics in the wake of the devastation wrought by the coronavirus.
The treaty guarantees that countries which share virus samples will receive tests, medicines and vaccines. Up to 20 % of such products would be given to the WHO to ensure poorer countries have some access to them when the next pandemic hits. WHO Director-General Tedros Adhanom Ghebreyesus has touted the agreement as 'historic' and a sign of multilateralism at a time when many countries are putting national interests ahead of shared values and cooperation.
While the effectiveness of the treaty is being undermined by the United States opting to sit this one out, it augurs well that other nations have come together to offer a broad swathe of protection to even people in nations who may not be able to afford the cost of newer vaccines or diagnostic facilities. Working on the principle, not of charity, but of the entrenched belief in public health that no one is safe until every one is safe, this pandemic agreement could make the difference between life and death for some people, in a crisis.
Incidentally, India reaffirms commitment to global health at World Health Assembly . India addressed the plenary session of the 78th World Health Assembly on Wednesday, (May 21, 2025) reaffirming its commitment to global health equity under the theme 'One World for Health', while reaffirming its faith in working together with other nations.
Staying on COVID, before we meander into the jungle of health news, FDA panel is split on updates to COVID shots as questions loom for fall vaccinations . Agencies reported that government advisors were split on whether drugmakers need to update their COVID-19 vaccines for next season, a decision overshadowed by confusion over a new Trump administration policy that may limit which Americans can get the shots. Earlier, the FDA said routine vaccine approvals will be limited to seniors and younger people with underlying medical risks, pending new research for healthy adults and children.
In other news on the infectious diseases front, we hear from Tamil Nadu that the State government has decided to expand its vaccination coverage, after a study flagged a rise in Japanese encephalitis cases . There has been a noticeable increase in cases (more than five cases) in districts outside of endemic areas such as Chennai, Kanchipuram, Chengalpattu and Tenkasi, the study found, spurring the government to action.
Soujanya Padikkal writes in the epaper on the newer antibiotics in the market and the emergent resistant strains too. As we continue to tackle the challenges of antimicrobial resistance, time to factor in newer, emergent issues , she says, while talking about the newer antibiotics molecules in the market and the pipeline. After nearly 30 years, new antibiotics are now available, and that does provide more tools in the armamentarium, but neither are our older microbial resistance issues in the part nor are our newer drugs immune to resistance. A tough task at hand for the government, which is being looked up to, to lead antibiotics stewardship.
Last week, I wrote about the Second Lancet Commission on adolescent health . It has recorded some gains; particularly in survival, but indicates need for more investments, laws to ensure the wellbeing of the largest bulwark of adolescents we will every have. There are several areas of concern mentioned, including climate change, the poverty of data, the impact of social media, non communicable diseases creeping up early, all impinging on the physical and mental health of adolescents and youth.
Relatedly, Dr. Pushkala M.S. examines why obesity in children is a growing concern in India . Two concerns present themselves - unhealthy diet choices, and lack of physical activity and will have to be addressed in a wholesome manner. Athira Elssa Johnson and Meghna M. write a detailed piece on why the CBSE's sugar board mandate is a starting point for integrating nutrition education into school curricula. The most effective interventions during childhood are eventually those that have been inculcated at the school. Dr. Maria Antony's article on how preferring Screentime over playtime will impact on children's mental health is an article every parent should read.
Dr. V. Mohan writes an elaborate article on prevention of diabetes, much before it begins, here . He explains that there are four types of prevention. Primordial prevention refers to a reduction of risk factors for diabetes such as obesity or physical inactivity, thereby decreasing the risk of developing prediabetes or diabetes in the future. Primary is prevention (or postponement) of diabetes in those in a pre-diabetes stage, while secondary prevention refers to the prevention of complications of diabetes in those who have already developed diabetes. There is also tertiary prevention which is used to describe limiting physical disability and preventing progression to end-stage complications in those who have already developed some complications of diabetes.
Fitness coach Raj Ganpath chimes in about what it is that prevents India from exercising enough and why this needs to change . He reasons that we come from a past of heavy physical labour and simple eating. While the concept of exercising did exist in a certain quarter, it was not essential to the culture or the society, because of the rather tough labour day most people had to endure.
R. Sujatha, meanwhile, had a piece following up on the WHO's advisory on using low sodium salt substitutes: Apparently, these are yet to take off in Chennai .
Keith Diaz, in a piece in The Conversation, also brings up the newer paradigm: Sitting is the new smoking! Too much sitting increases risk of future health problems in chest pain patients, as per new research.
Adding to the stress and the causative factors for the onset of non communicable diseases is the lack of sleep - another plague of modernity. Here, Dr. N. Ramakrishnan explains Why poor sleep and sleep deprivation are under-recognised public health issues .
Onto yet another kind of stress - this time, heat related. In a full-pager, Nandita Shivakumar and Apekshita Varshney ventured inside i nside Tamil Nadu's textile factories where they found women reel under harsh summer heat . There is certainly a major role for private factory managements and the government to ensure that effective cooling relief for their women workers, but it is also the responsibility of the global brands who contract work out to these units to ensure that the workers are in good health, they argue.
It turns out not just the women in the factories, about 3/4th of India's population is at 'high' to 'very high' heat risk. A CEEW study identified Delhi, Maharashtra, Goa, Kerala, Gujarat, Rajasthan, Tamil Nadu, as among the top 10 regions at highest heat risk. This is not going away with the monsoon showers. It will keep coming back in greater power, possibly, year on year, so it is best to prepare ourselves against the onslaught of the weather.
Have you heard of using oral sunscreens as sunblocks? Well, dermatologists say it is a myth . Dermatologists emphasise that supplements marketed as oral sunscreens are only supportive therapies and should never replace broad-spectrum topical sunscreen.
In an interesting development, an ICMR-funded trial led by CMC Vellore found that CAR-T therapy can be safely manufactured at hospital ; and experts have called for Early medical care for pelvic organ prolapse symptoms in order to improve the quality of life of women.
Tailpiece
Cat stories and jumbo stories pick themselves as internet's favourites. And here, this jumbo story is part of our tailpiece as well. Did you read about how 400 pills a day have to be fed to elephants with TB in Pakistan . This involves administering the tablets — the same as those used to treat TB in humans — hidden inside food ranging from apples and bananas to Pakistani sweets.
Explainers
Dr. C. Aravinda tries to explain the biology behind sterilisation: Going beyond the blame game: understanding sterilisation and its limits
Zubeda Hamid examines, on the lines of the U.S. Health Secretary RFK Jr.'s autism research push, what is actually needed for autism care?
Geetha Srimathi in the All you need to know about series, writes about Normal Pressure Hydrocephalus while Meenakshy S. writes vitiligo
P.S. Niranjana explains the history behind the iconic Caduceus symbol .
Manjeera Gowravaram asks: Does neurodegeneration start when blood vessels are damaged?
Also read:
Abhinay Lakshman Union government to launch fresh round of a nationwide survey to examine patterns of substance use
Dr. Monisha Madhumita Beyond fairness: marking International Skin Pigmentation Day with awareness and acceptance
Afshan Yasmeen Dementia — the urgent need for India to invest in elder care
Unregulated hair transplant practices in India: experts raise health and medical ethics concerns
Science quiz: On digestive health
Study validates India's first ICMR-SCD Stigma Scale for sickle cell diseas e
India partners with WHO to mainstream Ayush globally through agreement on traditional medicine interventions
For many more health stories, head to our health page and subscribe to the health newsletter here.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

COVID 19 Cases in India: Active Cases Rise To 4866, Delhi With 562 Cases- Kerala Leading The Chart With 1487 Cases
COVID 19 Cases in India: Active Cases Rise To 4866, Delhi With 562 Cases- Kerala Leading The Chart With 1487 Cases

India.com

time13 minutes ago

  • India.com

COVID 19 Cases in India: Active Cases Rise To 4866, Delhi With 562 Cases- Kerala Leading The Chart With 1487 Cases

COVID-19 Cases Rising In India Highlights: India is once again witnessing an unsettling rise in COVID-19 cases, with the number of active infections climbing to 4866, according to the Ministry of Health and Family Welfare's latest update as of 8:00 AM IST, June 5, 2025. Leading the current spike is Kerala pushing its active caseload to 1487, nearly half of the country's total. Meanwhile, West Bengal added 106 new cases, increasing its active tally to 538, while the national capital Delhi recorded 105 new infections, taking its active cases to 562. As per May 2025 classifications by the World Health Organization (WHO), subvariants LF.7 and NB.1.8.1 are categorized as Variants Under Monitoring, meaning they are not yet deemed as Variants of Concern or Variants of Interest. However, these strains are suspected to be contributing to the rising infections not just in India but also across China and other parts of Asia. Despite the emergence of new subvariants, the JN.1 strain remains the most dominant, accounting for a staggering 53% of all positive cases across the country. According to data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), a case of NB.1.8.1 was detected in Tamil Nadu in April, while four cases of LF.7 were identified in Gujarat earlier this month. With the virus subtly shifting form and symptoms evolving, health authorities are urging the public to maintain precautionary measures, including hygiene, mask use in crowded places, and timely testing. Although hospitalisation remains low, experts warn that complacency could reverse progress. Stay informed, and if you're experiencing mild symptoms like fatigue, a sore throat, or gastrointestinal discomfort, it's best to test early and isolate to prevent further spread.

A common drug shows promise for patients with liver disease
A common drug shows promise for patients with liver disease

Time of India

time17 minutes ago

  • Time of India

A common drug shows promise for patients with liver disease

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in treating severe liver conditions like MASH and liver fibrosis. The study, involving 154 participants, demonstrated significant improvements in MASH and fibrosis among those receiving dapagliflozin compared to the placebo group, suggesting a potential new treatment avenue. Liver disease accounts for two million deaths annually. This is 4% of all deaths (1 out of every 25 deaths worldwide), as per the data from 2023. Liver disease is a growing global health concern. A new study suggests that a widely used diabetes medication may offer hope for patients suffering from progressive liver disease. A recent clinical trial conducted in China and published in The BMJ suggests that the type 2 diabetes drug dapagliflozin can help patients with severe liver conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, which have limited treatment options. What does the diabetes drug do (Pic courtesy: iStock) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, which is widely used to treat type 2 diabetes, has been shown to improve progressive liver disease. The Chinese researchers found that the drug improved metabolic dysfunction-associated steatohepatitis (MASH), a condition where excess fat accumulates in the liver, leading to inflammation and liver fibrosis (a buildup of scar tissue). MASH affects more than 5% of adults, and it is also common (30%) in people with diabetes or obesity. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Switch to UnionBank Rewards Card UnionBank Credit Card Apply Now Undo This can progress to cirrhosis in up to 25% of individuals. Though previous studies have suggested that SGLT-2 inhibitors can improve liver fat content, liver enzymes, and liver stiffness, no trial has been carried out in patients with MASH. The study To understand the effects of dapagliflozin in patients with MASH, the researchers conducted a study. The 48-week study had 154 participants, who were diagnosed with MASH following liver biopsies at six Chinese medical centers from November 2018 to March 2023. Participants had an average age of 35, and 85% were men. Nearly half (45%0 had type 2 diabetes, and most had evidence of liver fibrosis at various stages (33% stage 1, 45% stage 2, 19% stage 3). Following an initial screening biopsy, the participants were randomly assigned to receive 10 mg of dapagliflozin or a matching placebo once daily for 48 weeks. They attended health education sessions twice a year. The researchers also recorded body weight, blood pressure, blood glucose, liver enzymes, physical activity, diet, insulin, and lipids of the participants throughout the trial. MASH improvement was defined as a decrease of at least 2 points in non-alcoholic fatty liver disease activity score (NAS) or a NAS of 3 points or less. By the end of the study, which is after 48 weeks, the researchers observed that 53% (41 of 78) participants in the dapagliflozin group showed improvement in MASH without worsening of fibrosis (defined as no increase in fibrosis stage) compared with 30% (23 of 76) in the placebo group. 23% (18 of 78) participants in the dapagliflozin group showed resolution of MASH without worsening of fibrosis, compared with 8% (6 of 76) in the placebo group. Trump Health Scare: 'Cognitive Decline' Spotted? Political Adviser's BIG Warning Amid Dementia Claim They also saw improvement in fibrosis without worsening of MASH in 45% (35 of 78) participants in the dapagliflozin group compared with 20% (15 of 76) in the placebo group. 1% (1 of 78) in the dapagliflozin group and 3% (2 of 76) in the placebo group discontinued the treatment because of adverse events. What are the experts saying Fatty liver 'Our findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis,' they said. They added that large-scale and long-term trials are needed to further confirm these effects. The trial was conducted in a Chinese population, which limits its broader generalisability. They also noted that with the emergence of more drugs, therapeutic decisions will likely become increasingly tailored to individual patient profiles, they write. 'Ideally, such treatments should provide cardiovascular benefit, have an established safety profile, and be accessible to broad and diverse patient populations,' they concluded. One step to a healthier you—join Times Health+ Yoga and feel the change

TTD issues Covid alert in Tirumala
TTD issues Covid alert in Tirumala

New Indian Express

time29 minutes ago

  • New Indian Express

TTD issues Covid alert in Tirumala

TIRUMALA: The Tirumala Tirupati Devasthanams (TTD) has sounded a COVID-19 alert on Wednesday, urging both employees and visiting pilgrims to follow precautionary measures in view of rising cases. On Wednesday evening, the TTD administration issued an emergency circular to all department heads and staff, directing strict implementation of health and safety guidelines issued by the Director of Public Health and Family Welfare. The circular emphasised enhanced vigilance in high-traffic areas such as queue complexes, accommodation blocks, and other public spaces within the Tirumala temple premises. It also called for the immediate suspension of mass gatherings, including prayer meetings, parties, and social functions. Elderly individuals and pregnant women have been advised to take extra precautions in view of Covid resurgence.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store